相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The effect of switching from teriparatide to anti-RANKL antibody on cancellous and cortical bone in ovariectomized mice
Toshinobu Omiya et al.
BONE (2018)
A Novel Diterpenoid Suppresses Osteoclastogenesis and Promotes Osteogenesis by Inhibiting Ifrd1-Mediated and IB-Mediated p65 Nuclear Translocation
Zi'ang Xie et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Kit W-sh Mutation Prevents Cancellous Bone Loss during Calcium Deprivation
Sutada Lotinun et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
The Scaffolding Protein IQGAP1 Interacts with NLRC3 and Inhibits Type I IFN Production
Aaron M. Tocker et al.
JOURNAL OF IMMUNOLOGY (2017)
Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis
T. Saito et al.
OSTEOPOROSIS INTERNATIONAL (2017)
PTH[1-34] improves the effects of core decompression in early-stage steroid-associated osteonecrosis model by enhancing bone repair and revascularization
Chen-he Zhou et al.
PLOS ONE (2017)
Gα13 negatively controls osteoclastogenesis through inhibition of the Akt-GSK3β-NFATc1 signalling pathway
Mengrui Wu et al.
NATURE COMMUNICATIONS (2017)
Osteoporosis treatment: recent developments and ongoing challenges
Sundeep Khosla et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
New horizons in osteoporosis therapies
Torben Harslof et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
NLRC3 is an inhibitory sensor of PI3K-mTOR pathways in cancer
Rajendra Karki et al.
NATURE (2016)
Cepharanthine inhibits in vitro VSMC proliferation and migration and vascular inflammatory responses mediated by RAW264.7
Keshav Raj Paudel et al.
TOXICOLOGY IN VITRO (2016)
GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation
Weiqing Liu et al.
NATURE COMMUNICATIONS (2016)
Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways
Feng-Lai Yuan et al.
BONE (2015)
Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo
Shuai Chen et al.
SCIENTIFIC REPORTS (2015)
Osteoclasts: more than 'bone eaters'
Julia F. Charles et al.
TRENDS IN MOLECULAR MEDICINE (2014)
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis
Nelson Watts et al.
Endocrine Practice (2013)
Disruption of the Dynein-Dynactin Complex Unveils Motor-Specific Functions in Osteoclast Formation and Bone Resorption
Pei Ying Ng et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation
Sutada Lotinun et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates
Yu-Bing Zhou et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
Low dose cepharanthine ameliorates immune thrombocytopenic purpura associated with multiple myeloma
Rie Tabata et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2012)
The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB
Monika Schneider et al.
NATURE IMMUNOLOGY (2012)
International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis
Samuel Vasikaran et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
Bone resorption in syndromes of the Ras/MAPK pathway
D. A. Stevenson et al.
CLINICAL GENETICS (2011)
Blocking of sodium and potassium ion-dependent adenosine triphosphatase-α1 with ouabain and vanadate suppresses cell-cell fusion during RANKL-mediated osteoclastogenesis
Seicho Makihira et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Emerging therapeutic opportunities for skeletal restoration
Masanobu Kawai et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions
Moshe Rogosnitzky et al.
PHARMACOLOGICAL REPORTS (2011)
Bone Turnover Markers and Prediction of Fracture: A Prospective Follow-Up Study of 1040 Elderly Women for a Mean of 9 Years
Kaisa K. Ivaska et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Femoral Cortical Stress Lesions in Long-Term Bisphosphonate Therapy: A Herald of Impending Fracture?
Joyce S. B. Koh et al.
JOURNAL OF ORTHOPAEDIC TRAUMA (2010)
Neridronic acid for the treatment of bone metabolic diseases
Davide Gatti et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-κB pathway
Naoko Takahashi-Makise et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Bisphosphonate Associated Osteonecrosis of the Jaw
Aliya A. Khan et al.
JOURNAL OF RHEUMATOLOGY (2009)
RANK/RANKL: Regulators of Immune Responses and Bone Physiology
Andreas Leibbrandt et al.
YEAR IN IMMUNOLOGY 2008 (2008)
Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines
Masamichi Ita et al.
CANCER BIOLOGY & THERAPY (2008)
National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): What They Mean to the Bone Densitometrist and Bone Technologist
Nelson B. Watts et al.
JOURNAL OF CLINICAL DENSITOMETRY (2008)
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025
Russel Burge et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: Implications for cancer, shock, and inflammatory diseases
Shinobu Furusawa et al.
LIFE SCIENCES (2007)
Cost-effectiveness strategies to treat osteoporosis in elderly women
Alfred K. Pfister et al.
SOUTHERN MEDICAL JOURNAL (2006)
Inhibition of Na+,K+-ATPase by the extract of Stephania cephararantha HAYATA and bisbenzylisoquinoline alkaloid cycleanine, a major constituent
K Satoh et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Osteoclast differentiation and activation
WJ Boyle et al.
NATURE (2003)
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts
H Takayanagi et al.
DEVELOPMENTAL CELL (2002)
Seventeen cases of alopecia areata: Combination of SADBE topical immunotherapy with other therapies
K Morita et al.
JOURNAL OF DERMATOLOGY (2002)
Summary of meta-analyses of therapies for postmenopausal osteoporosis
A Cranney et al.
ENDOCRINE REVIEWS (2002)
Suppression of cytokine production and neural cell death by the anti-inflammatory alkaloid cepharanthine: a potential agent against HIV-1 encephalopathy
M Okamoto et al.
BIOCHEMICAL PHARMACOLOGY (2001)
分享论文
